John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Lopes, Renato D., Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, et al. “Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil..” J Thromb Thrombolysis 32, no. 2 (August 2011): 242–66. https://doi.org/10.1007/s11239-011-0592-7.

PMID
21547405
Full Text

Becker, Richard C., Hongqiu Yang, Yuchen Barrett, Puneet Mohan, Jessie Wang, Lars Wallentin, and John H. Alexander. “Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor..” J Thromb Thrombolysis 32, no. 2 (August 2011): 183–87. https://doi.org/10.1007/s11239-011-0591-8.

PMID
21516308
Full Text

Mehta, Rajendra H., T Bruce Ferguson, Renato D. Lopes, Gail E. Hafley, Michael J. Mack, Nicholas T. Kouchoukos, C Michael Gibson, et al. “Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial..” Circulation 124, no. 3 (July 19, 2011): 280–88. https://doi.org/10.1161/CIRCULATIONAHA.110.991299.

PMID
21709060
Full Text

Povsic, T. J., M. G. Cohen, M. Y. Chan, S. L. Zelenkofske, W. A. Wargin, R. A. Harrington, J. H. Alexander, C. P. Rusconi, and R. C. Becker. “Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design..” J Thromb Thrombolysis 32, no. 1 (July 2011): 21–31. https://doi.org/10.1007/s11239-011-0588-3.

PMID
21503856
Full Text

Leiria, Tiago L. L., Renato D. Lopes, Judson B. Williams, Jason N. Katz, Renato A. K. Kalil, and John H. Alexander. “Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician..” J Thromb Thrombolysis 31, no. 4 (May 2011): 514–22. https://doi.org/10.1007/s11239-011-0574-9.

PMID
21327503
Full Text

Povsic, T. J., M. G. Cohen, M. Y. Chan, S. L. Zelenkofske, W. A. Wargin, R. A. Harrington, J. H. Alexander, C. P. Rusconi, and R. C. Becker. “Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design.” Journal of Thrombosis and Thrombolysis, April 20, 2011, 1–11. https://doi.org/10.1007/s11239-011-0588-3.

Full Text

Domanski, Michael J., Kenneth Mahaffey, Vic Hasselblad, Sorin J. Brener, Peter K. Smith, Graham Hillis, Milo Engoren, et al. “Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery..” Jama 305, no. 6 (February 9, 2011): 585–91. https://doi.org/10.1001/jama.2011.99.

PMID
21304084
Full Text

Povsic, Thomas J., Mauricio G. Cohen, Roxana Mehran, Christopher E. Buller, Christoph Bode, Jan H. Cornel, Jarosław D. Kasprzak, et al. “A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial..” Am Heart J 161, no. 2 (February 2011). https://doi.org/10.1016/j.ahj.2010.10.022.

PMID
21315207
Full Text

Alexander, J. “SY06-5 Apixaban for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Primary Results of the ARISTOTLE Trial.” Journal of Arrhythmia 27 (January 1, 2011). https://doi.org/10.4020/jhrs.27.SY06_5.

Full Text

Mehta, Rajendra H., Amanda Stebbins, Renato D. Lopes, Sunil V. Rao, Eric R. Bates, Karen S. Pieper, Paul W. Armstrong, et al. “Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy..” Am J Med 124, no. 1 (January 2011): 48–57. https://doi.org/10.1016/j.amjmed.2010.07.028.

PMID
21187185
Full Text

Pages